Loading...
OTCM
BIOAF
Market cap15kUSD
Jul 11, Last price  
0.00USD
1D
0.00%
Jan 2017
-99.98%
IPO
-99.97%
Name

Bioasis Technologies Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
10.52%
Revenues
0k
-100.00%
000000000369,124512,966589,8441,422,030606,3844,078,12937,7250
Net income
0k
P
-5,000-131,131-1,149,785-2,217,690-2,142,710-2,937,907-4,960,765-3,610,124-2,836,269-2,572,923-2,990,781-5,307,938-3,473,414-4,056,420698,410-2,960,0920
CFO
0k
P
0-61,816-547,566-1,460,135-1,390,757-1,782,285-1,865,123-2,824,320-2,015,153-1,530,218-1,244,213-3,673,138-3,229,675-3,298,6521,771,476-3,635,5050

Profile

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.
IPO date
Jul 24, 2007
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑022022‑022021‑022020‑022019‑022018‑022017‑022016‑02
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
216
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
78,213
Price
0.02
-92.59%
Market cap
1,564
-91.97%
EV
1,564
EBITDA
EV/EBITDA
Interest
Interest/NOPBT